Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.362 – $0.443
Volume61,085
Market cap$6M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.82M
Price / earnings
—
Price / book
-1.81×
Price / sales
—
EV / sales
—
EV / EBITDA
0.05×
Profitability
Earnings per share
-$1.25
Return on assets
-216.84%
Return on equity
579.78%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
1.96×
Quick ratio
1.96×
Cash ratio
1.54×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$14.08M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LTRN, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.72M
$1.68M
$1.46M
$1.91M
$1.58M
$1.51M
$1.63M
$1.46M
Research and development
$1.79M
$1.72M
$2.74M
$2.44M
$3.07M
$3.26M
$4.27M
$3.72M
Total operating expenses
$3.51M
$3.41M
$4.2M
$4.35M
$4.65M
$4.77M
$5.9M
$5.18M
Operating income
-$3.51M
-$3.41M
-$4.2M
-$4.35M
-$4.65M
-$4.77M
-$5.9M
-$5.18M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$7.07M
-$3.33M
-$4.07M
-$4.18M
-$4.33M
-$4.54M
-$5.88M
-$4.51M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$7.07M
-$3.33M
-$4.07M
-$4.18M
-$4.33M
-$4.54M
-$5.88M
-$4.51M
Net income attributable to common shareholders
-$7.07M
-$3.33M
-$4.07M
-$4.18M
-$4.33M
-$4.54M
-$5.88M
-$4.51M
EBITDA
-$3.5M
-$3.4M
-$4.2M
-$4.35M
-$4.65M
-$4.77M
-$5.89M
-$5.18M
Basic earnings per share
-$0.57
-$0.30
-$0.36
-$0.39
-$0.40
-$0.42
-$0.54
-$0.42
Diluted earnings per share
-$0.57
-$0.30
-$0.36
-$0.39
-$0.40
-$0.42
-$0.54
-$0.42
Recent news
Company coverage with links to the original publishers.
Lantern Pharma, an AI-driven biotech company, is using machine learning and computational biology to accelerate cancer drug discovery, with three ongoing clinical trials targeting challenging and rare cancers.
Lantern Pharma, an AI-driven oncology biotech, reported improved Q2 2025 financial results with narrowed GAAP losses and promising clinical trial progress across multiple drug candidates, particularly in cancer treatments.
Lantern, a specialty care platform, announced a new partnership with the 32BJ Health Fund to provide access to high-quality surgeons and specialists at little to no cost for the union's members. This partnership aims to ensure affordable and accessible healthcare for the essential workforce represented by SEIU 32BJ.
Actuate Therapeutics and Lantern Pharma are collaborating to accelerate the development of Actuate's lead drug candidate, elraglusib, and enable the screening for additional biomarkers to assess and predict its therapeutic activity and clinical outcomes.
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.
United Natural Foods posted adjusted earnings of 7 cents per share, compared to market estimates for a loss of 1 cent per share. The company’s quarterly sales came in at $7.78 billion, versus expectations of $7.87 billion, according to data from Benzinga Pro.
United Natural Foods named Giorgio Matteo Tarditi as President and Chief Financial Officer.
United Natural Foods shares dipped 15.2% to $12.61 on Wednesday.
Here are some other stocks moving in today's mid-day session.
Gainers
Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 115.2% to $4.24. Rail Vision announced first commercial installation of its AI-driven main line systems in a national railways line.
Aptorum Group Limited (NASDAQ: APM) shares climbed 90.1% to $3.1750. Aptorum Group announced an agreement and plan of merger with YOOV Group Holding Ltd and a split-off agreement to separate its legacy business.
NKGen Biotech, Inc. (NASDAQ: NKGN) gained 46.5% to $1.35.
TRxADE HEALTH, Inc. (NASDAQ: MEDS) rose 39.2% to $11.19 after the company announced a special cash dividend of $8 per share.
Airship AI Holdings, Inc. (NASDAQ: AISP) shares climbed 37.8% to $6.82. Airship AI Holdings shares jumped 200% on Tuesday after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform.
Enviva Inc. (NYSE: EVA) rose 33% to $0.9854 after gaining 42% on Tuesday.
American Public Education, Inc. (NASDAQ: APEI) gained 31.8% to $14.99 following upbeat quarterly results.
Dada Nexus Limited (NASDAQ: DADA) climbed 30.6% to $2.5740. Dada Nexus said certain revenues and associated costs were overstated in past financial statements.
Cemtrex, Inc. (NASDAQ: CETX) gained 30% to $4.4361. Cemtrex announced beta release of pioneering AI gun detection feature.
Wave Life Sciences Ltd. (NYSE: WVE) gained 28.5% to $6.16 following upbeat quarterly results.
Vincerx Pharma, Inc. (NASDAQ: VINC) shares gained 24.5% to $6.89. Vincerx will present three posters at the American Association for Cancer Research (AACR) Annual Meeting 2024.
XORTX Therapeutics Inc. (NASDAQ: XRTX) rose 24.2% to $5.85.
CareMax, Inc. (NASDAQ: CMAX) gained 23.8% to ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.